Loading...

Takara Bio Inc.

TKBIFPNK
Healthcare
Biotechnology
$23.20
$0.00(0.00%)

Takara Bio Inc. (TKBIF) Company Profile & Overview

Explore Takara Bio Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Takara Bio Inc. (TKBIF) Company Profile & Overview

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing. In addition, the company is involved in developing platform technology for biologics development in areas, such as gene therapy. The company was incorporated in 2002 and is based in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

SectorHealthcare
IndustryBiotechnology
CEOKoichi Nakao

Contact Information

81 77 565 6920
7-4-38 Nojihigashi, Kusatsu, 525-0058

Company Facts

1,838 Employees
IPO DateApr 27, 2020
CountryJP

Frequently Asked Questions

;